CancerDrs

Lung Cancer clinical trials in Kentucky

28 actively recruiting lung cancer trials at 15 sites across Kentucky.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Kentucky:
  • King's Daughter's Medical Center — Ashland, Kentucky
  • Flaget Memorial Hospital — Bardstown, Kentucky
  • Baptist Health Corbin — Corbin, Kentucky
  • Commonwealth Cancer Center-Corbin — Corbin, Kentucky
  • Baptist Health Hardin — Elizabethtown, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Sites in Kentucky:
  • Owensboro Health Mitchell Memorial Cancer Center — Owensboro, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …

Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Kentucky:
  • University of Kentucky Chandler Medical Center — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …

Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Kentucky:
  • Research Site — Lexington, Kentucky
  • Research Site — Lexington, Kentucky
  • Research Site — Louisville, Kentucky
  • Research Site — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Kentucky:
  • Saint Elizabeth Medical Center Edgewood — Edgewood, Kentucky
  • Baptist Health Lexington — Lexington, Kentucky
  • Local Institution - 0502 — Paducah, Kentucky
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…

Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Kentucky:
  • Baptist Health Hardin — Elizabethtown, Kentucky
  • Baptist Health Lexington — Lexington, Kentucky
  • University of Kentucky Chandler Medical Center (UKCMC) - Markey Cancer Center (Lucille P. Markey Cancer Center) — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…

Sponsor: AbbVie
NCT ID: NCT04928846
Sites in Kentucky:
  • Baptist Health Lexington /ID# 252769 — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

Sponsor: AstraZeneca
NCT ID: NCT06868277
Sites in Kentucky:
  • Research Site — Lexington, Kentucky
  • Research Site — Owensboro, Kentucky
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival w…

Sponsor: Boehringer Ingelheim
NCT ID: NCT07472517
Sites in Kentucky:
  • Norton Cancer Institute, Downtown — Louisville, Kentucky
  • Pikeville Medical Center — Pikeville, Kentucky
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Kentucky:
  • Flaget Memorial Hospital — Bardstown, Kentucky
  • Commonwealth Cancer Center-Corbin — Corbin, Kentucky
  • Saint Joseph Hospital — Lexington, Kentucky
  • Saint Joseph Radiation Oncology Resource Center — Lexington, Kentucky
  • Saint Joseph Hospital East — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

Sponsor: AstraZeneca
NCT ID: NCT05797168
Sites in Kentucky:
  • Research Site — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Local…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07680764
Sites in Kentucky:
  • Local Institution - 0034 — Lexington, Kentucky
  • Local Institution - 0171 — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).

Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT05361174
Sites in Kentucky:
  • University of Louisville — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertini…

Sponsor: Genprex, Inc.
NCT ID: NCT04486833
Sites in Kentucky:
  • Markey Cancer Center — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

This is a first-in-human (FIH), open-label, multi-site study which will evaluate the safety, efficacy, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid tumors.

Sponsor: BioNTech SE
NCT ID: NCT06750185
Sites in Kentucky:
  • Norton Cancer Institute PARENT — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)

Sponsor: Teligene US
NCT ID: NCT05168566
Sites in Kentucky:
  • Baptist Health — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

This is a Phase II, multisite, open-label study consisting of two parts in participants with advanced/metastatic Non-small Cell Lung Cancer (NSCLC) which progressed after a first-line chemoimmunotherapy to evaluate the combination of pumit…

Sponsor: BioNTech SE
NCT ID: NCT06841055
Sites in Kentucky:
  • Baptist Health Hardin — Elizabethtown, Kentucky
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

Researchers are looking for other ways to treat metastatic squamous non-small cell lung cancer (NSCLC). Squamous NSCLC is cancer that starts in squamous cells, which are flat cells that line the inside of the airways in the lungs. Metastat…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06780098
Sites in Kentucky:
  • University of Kentucky Chandler Medical Center ( Site 0019) — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary effic…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT07564401
Sites in Kentucky:
  • University of Kentucky — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

This is a Phase II clinical study for people with stage IV cancer. The study will evaluate the use of stereotactic body radiation therapy (SBRT), a type of focused radiation treatment, together with immunotherapy-based treatment. SRBT will…

Sponsor: Mark Bernard
NCT ID: NCT07770100
Sites in Kentucky:
  • University of Kentucky Markey Cancer Center — Lexington, Kentucky
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expa…

Sponsor: Amgen
NCT ID: NCT07037758
Sites in Kentucky:
  • Norton Cancer Institute - Downtown — Louisville, Kentucky
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic …

Sponsor: Orano Med Theranostics, SAS
NCT ID: NCT05283330
Sites in Kentucky:
  • UK Markey Cancer Center — Lexington, Kentucky
View on ClinicalTrials.gov →

Showing 25 of 28 trials with sites in Kentucky. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19